Mark Peterson

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

Sachem Capital's dividend announcement reveals a ~19% yield. We dissect the strategy of this mortgage REIT and its role as a disruptor in private lending.

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

Virax secured a $5M runway for its Long COVID diagnostics, but the deal's terms reveal a high-stakes gamble involving significant shareholder dilution.

Riot Platforms' latest update shows more than mining numbers; it reveals a strategic shift using Bitcoin to fund a major pivot into AI data centers.

Lion Group is diversifying its crypto-heavy treasury with Bitcoin. Is this a savvy move in a cool market or a high-stakes bet for a volatile company?

The medtech giant projects robust growth with an ambitious pipeline, but a high-stakes regulatory showdown over a key acquisition could redefine its future.

As the MASH market shifts beyond monotherapy, Galmed's new patent for a combo with Rezdiffra is a strategic move to own a piece of the next-gen solution.

Heron Therapeutics' APONVIE just got a major endorsement. How this single guideline change could reshape patient recovery and shake up the anti-nausea market.

With a $44M war chest and a key crypto acquisition, Thumzup is ditching social media for blockchain and AI. A bold market disruption in the making.

Citius Oncology's partnership with Er-Kim is more than a distribution deal; it's a strategic masterclass in bringing hope to underserved patients.

As GPS jamming cripples drones on the battlefield, AeroVironment’s new visual navigation system for its Puma fleet marks a critical strategic shift.

Powersports maker Massimo Group is pivoting into the competitive robotics market. Can its manufacturing DNA overcome financial hurdles and tech giants?

Display giant AUO is building a powerful smart healthcare ecosystem, using 3D imaging and AI to redefine surgery, diagnostics, and even traditional medicine.